About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
P&T welcomes Dr. Baumel, the newest addition to our editorial board.
The author reviews new warnings and label changes for sirolimus (Rapamune®), pergolide mesylate (Permax®), and salmeterol xinafoate inhalation aerosol (Serevent®).
Marvin M. Goldenberg, PhD, RPh, MS
A practicing physician relates the story of the best $4 he ever spent.
Thomas Marzili, MD
The authors present an in-depth review of Rebif® for prevention of relapses in patients with MS.
Abby Guest, PharmD Candidate, and Richard Cramer, PharmD
Determining the expenditures related to RSV infection requires diagnostic confirmation, a chart review, and an analysis of billing costs.
Ben Z. Katz, MD, Joseph Lo, MPH, and Mark Sorrentino, MD, MS
Dr. Prescott reviews drug-coated stents, beta blockade, a thrombin inhibitor, a new statin, a lipid-lowering formulation, and other advances presented at the ACC meeting.
Lawrence M. Prescott, PhD
Daniel McDevitt, MD, FACS
Editor-in-Chief David Nash, MD, MBA, puts a new “spin” on some commonly used jargon in P&T committees.
David B. Nash, MD, MBA
Matthew Grissinger discusses a set of “tools” for preventing medication errors.
Matthew Grissinger, RPh
Stephen Barlas describes the new bar-code proposal for hospitals.
The authors review peg-interferon alfa-2a (Pegasys®) for the treatment of hepatitis C virus infection.
Tarrah Williams, PharmD Candidate, Marlon Honeywell, PharmD, Evans Branch III, PharmD, and Michael Thompson, BCNSP, PharmD
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA